Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies

Shu Fang; Nan Wang; Lili Wang; Jishan Du; Jingjing Yang; Yanan Wen; Yan Wei; Kun Qian; Hao Wang; Yifan Jiao; Chunji Gao; Liping Dou

doi:10.12659/AOT.937356

11 October 2022 : Original article

Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies

Shu Fang^12ABCDEF, Nan Wang^23ABCF, Lili Wang^2ABCD, Jishan Du^23BCF, Jingjing Yang^23BCF, Yanan Wen^23BCF, Yan Wei^23BCF, Kun Qian^12BCD, Hao Wang^23ABF, Yifan Jiao^23BCF, Chunji Gao^12ACEG*, Liping Dou^2ABDEG

DOI: 10.12659/AOT.937356

Ann Transplant 2022; 27:e937356

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 4 Multivariate analysis of risk factors for transplant outcomes in all patients.

Variables	HR	95% CI	p
Grades 2–4 aGVHD
Donor-recipient ABO match
Mismatch vs match	1.978	0.933–4.192	0.075
Time interval between diagnosis and HSCT
≥6 m vs <6 m	2.032	0.943–4.380	0.070
CD34 (≥ median vs < median)	1.976	0.911–4.289	0.085
Chronic GVHD
Diagnosis (ALL vs others)	0.791	0.288–2.173	0.650
ATG vs non-ATG	0.251	0.108–0.582	0.001
Disease risk index
High/very high vs low/intermediate	0.414	0.158–1.083	0.072
Moderate to severe cGVHD
ATG vs non-ATG	0.314	0.103–0.958	0.042
Recipient age (≥ median vs < median)	0.428	0.161–1.143	0.090
Extensive cGVHD
ATG vs non-ATG	0.269	0.073–0.995	0.049
CIR
Diagnosis (ALL vs others)	1.536	0.728–3.241	0.260
ATG vs non-ATG	2.337	1.133–4.822	0.022
Time interval between diagnosis and HSCT
≥6 m vs < 6 m	0.520	0.253–1.071	0.076
GRFS
Disease risk index
High/very high vs low/intermediate	1.654	0.979–2.792	0.060
CD34 (≥ median vs < median)	1.785	1.067–2.984	0.027
OS
Time interval between diagnosis and HSCT
≥6 m vs <6 m	0.559	0.266–1.176	0.125
DFS
Time interval between diagnosis and HSCT
≥6 m vs <6 m	0.593	0.311–1.133	0.114
ATG – anti-thymocyte globulin; aGVHD – acute graft-versus-host disease; cGVHD – chronic graft-versus-host disease; HSCT – hematopoietic stem cell transplantation; ALL – acute lymphoblastic leukemia; CR – complete remission; MNCs – mononuclear cells.

Back to the Article

Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies

Your Privacy